Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.50 |
| ▸ | SCN4A | P35499 | 2/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97377 | 0.81 | LMNA (0.68) | LMNAMAOAPTGS1CYP2D6MTNR1A | |
| SCHEMBL9178337 | 0.81 | LMNA (0.68) | LMNAMAOAPTGS1CYP2D6MTNR1A | |
| SCHEMBL13385106 | 0.81 | LMNA (0.68) | LMNAMAOAPTGS1CYP2D6MTNR1A | |
| SCHEMBL544769 | 0.79 | LMNA (0.66) | LMNAMAOAPTGS1CYP2D6MTNR1A | |
| Ammonia Solution, Strong SCHEMBL28834669 | 0.79 | LMNA (0.65) | LMNAMAOAPTGS1CYP2D6MTNR1A | |
| SCHEMBL4048803 | 0.78 | KCNA3 (0.54) | LMNAMAOAPTGS1KCNA3MAPK1 | |
| SCHEMBL11415636 | 0.78 | LMNA (0.59) | LMNAMAOAPTGS1CYP2D6MTNR1A | |
| SCHEMBL16166837 | 0.78 | LMNA (0.53) | LMNAMAOAPTGS1CYP2D6MTNR1A | |
| SCHEMBL4040631 | 0.78 | LMNA (0.53) | LMNAMAOAPTGS1CYP2D6MTNR1A | |
| SCHEMBL24161002 | 0.77 | LMNA (0.63) | LMNAMAOAPTGS1CYP2D6MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-31 | — | — | US | disclosed |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| US-20180258038-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-10064879-B2 | Method for treating depression and/or depression status with substituted quinoxaline compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-04 | — | — | US | disclosed |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-4886809-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| EP-0297923-A1 | Benzodioxane prostacyclin analogues, their preparation and use | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1989-01-04 | — | — | EP | disclosed |
| EP-0290280-A2 | Anti-tumor platinum complexes, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1988-11-09 | — | — | EP | disclosed |
| US-4737501-A | Substituted piperazinyl oxindol compounds and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-12 | — | — | US | disclosed |
| EP-0255134-A2 | Carbostyril derivatives and salts thereof, process for preparing them, and cardiotonic composition containing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-03 | — | — | EP | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
| EP-0168003-A1 | Oxindol compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-15 | — | — | EP | disclosed |
| US-4302588-A | 5-(3-SUBSTITUTED AMINO)-2-HYDROXY-PROPYLOXY)-8-HYDROXY OR ALKOXY-CARBOSTYRILS, ADRENERGIC BLOCKING AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-11-24 | — | — | US | disclosed |
| US-4289883-A | ADRENERGIC BLOCKING AGENTS OF EXCELLENT CARDIOSELECTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-15 | — | — | US | disclosed |
| US-4147869-A | ADRENERGIC BLOCKING AGENTS FOR TREATMENT OF ANGINA PECTORIS, ARRHYTHMIA AND HYPERTENSION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | LMNA 258/4885MAOA 134/4885PTGS1 1536/4885 |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | LMNA 437/4885MAOA 51/4885PTGS1 1358/4885 |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | SLC6A2, TPH1, SLC6A3 | LMNA 3720/4885MAOA 6/4885PTGS1 1821/4885 |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | LMNA 1124/4885MAOA 143/4885PTGS1 2734/4885 |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | MC2R, PNMT, SLC6A2 | LMNA 730/4885MAOA 72/4885PTGS1 1891/4885 |
| US-20180258038-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | SLC6A2, TPH1, SLC6A3 | LMNA 3720/4885MAOA 6/4885PTGS1 1821/4885 |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | LMNA 2177/4885MAOA 3153/4885PTGS1 637/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | LMNA 1817/4885MAOA 3145/4885PTGS1 180/4885 |
| US-10064879-B2 | Method for treating depression and/or depression status with substituted quinoxaline compounds | KYNU, CRH, CHRM1 | LMNA 552/4885MAOA 157/4885PTGS1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.